By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said this week that its subsidiary, CombiMatrix Molecular Diagnostics, has received approval from Medicare to begin billing for its array-based diagnostic tests. The subsidiary offers array-based cancer tests through its Irvine, Calif.-based CLIA-certified lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.